1 flagged vendor.
Evidence visible.

Certificate provenance and integrity

The ten lot certificates Costides publishes come from two laboratories that cannot be independently verified. Biolumin Labs (retatrutide 10, 20 and 30 mg tested 2026-09-14 and issued 2026-09-17; KPV and MOTS-c tested 2026-10-02 and issued 2026-10-05) prints only a website and an email address, with no street address or accreditation, and bioluminlabs.com was registered on 2026-09-16, two days after the retatrutide test date. Calvert Spectrometry (tirzepatide, tesamorelin, GHK-Cu and Wolverine analysed 2026-10-01 and reported 2026-10-03; KLOW dated 2026-10-09) prints "Fremont, CA 94538" with no street address or accreditation number, and calvertspectrometry.com was registered on 2026-09-21. The certificates fail internal checks: net content outside their own 95–105% specification with no fail flag (retatrutide 11.72 mg on 10 mg, 21.03 mg on 20 mg, 32.39 mg on 30 mg; KPV 10.92 mg on 10 mg); the retatrutide identity ion is specified as [M+3H]3+ but captioned [M+H]+; the microbial screen reads "No Test" (GHK-Cu) and "NO SCREENING (N/A)" (tirzepatide) with no exception flag; the GHK-Cu, tesamorelin and tirzepatide chromatograms share identical peak widths and heights; the four Calvert PDFs were created on 2026-10-10 and 2026-10-15, after their printed report date; the KLOW certificate has no accession, report number, signature or specification column, and Calvert's lookup matches the other four lots but not KLOW. Peptide Critic published its own analysis on 2026-09-27 ("Costides, Biolumin Labs, and the COAs That Don't Add Up"). Re-checked 2026-10-19: the three retatrutide PDFs are byte-identical to the copies downloaded in September, and the vendor publishes no legal entity or street address.